AboutTechnologyClinicalPipeline SolutionsInvestorsNews PartnersTeamContact
The First Bio-Fabless Diagnostics Company

Where Silicon Meets Biology

Novascope is redefining in-vitro diagnostics by uniting semiconductor engineering and biochemistry. Our BioIC platform delivers clinical answers in minutes — not days — across infectious disease, neurodegeneration, and oncology.

98%*
Accuracy (n=88)
<60
Min to Result
$22.5M
Capital Raised
40+
Patents Filed
Validated at CGMH (IRB-approved) Manufactured by UMC ISO 13485 Certified FDA Establishment Registered

*Single-center, n=88 clinical samples, IRB-approved protocol at Chang Gung Memorial Hospital. Data on file.

ISO 13485 Certified FDA Establishment Registered 40+ Patents Filed IRB-Approved Clinical Data UMC Foundry Partner
About Us

The BioSemiconductor Company

Novascope BioChips Inc. is a BioIC company — applying the rigor, scalability, and design discipline of CMOS-based integrated circuits to the complexity of biomolecular detection. We have built a fully integrated, end-to-end IVD platform that transforms how diseases are diagnosed.

Our Mission

To bring semiconductor economics into clinical diagnostics — making fast, affordable, precision testing accessible from reference laboratories to point-of-care clinics worldwide.

Our Vision

A world where any charged biomolecule — DNA, RNA, proteins, or metabolites — can be detected at the point of need, at semiconductor cost, in minutes. From lab medicine to community clinics to the developing world.

Company Snapshot

2022
Founded
50+
Employees
$22.5M
Capital Raised
40+
Patents Filed

Milestones

2022

Founded — Taiwan & US

Company incorporated in Hsinchu, Taiwan and San Diego, CA. Core IC design and biochemistry team assembled.

2023

Series A — 50+ Employees

ISO 13485 clean room laboratory established. First chip generations fabricated at UMC.

2024

Clinical Validation — 6 Chip Generations

98% accuracy sepsis detection (n=88, CGMH). R²=0.97 NfL vs. SIMOA. 77 antibody clones developed. FDA Class I listed. Pilot production 5K chips/month.

2025

Series B — $22.5M Total Raised

40+ patents filed worldwide. NVDFlow™ automated platform completed. Multi-center trial preparation.

2026–27

Multi-Center Clinical Trials

TFDA & FDA regulatory submissions. GMP manufacturing scale-up. Commercial launch preparation.

2028

First Regulated Product Launch

Revenue inflection from diagnostic products. Expansion into oncology and veterinary markets.

Technology

A New Paradigm for Clinical Diagnostics

Novascope is redefining in-vitro diagnostics (IVD) by uniting two historically separate disciplines: semiconductor engineering and biochemistry. The integration of semiconductor technology and biochemical expertise allows our platform to achieve high-density multiplexing, intrinsic on-chip controls, and exceptional signal fidelity.

End-to-End Solutions: Where Biochemistry Meets Semiconductors

Detection based on the change of electric charge distribution at the NovaCHIP™ surface after analyte binding

Enabling Engine Value-Added Services NovaCHIP™ Platform Core NovaCHIP™ ASIC Chip Design NovaLINK™ Surface Chemistry NovaBIO™ Bio-Probes & Reagents NovaCRO™ Biobank & CRO Lab NovaKIT™ Reader & Cartridge NVDFlow™ Automated Platform NovaAI™ Signal Intelligence Software Hospital Integration
Novascope
Platform

NovaCHIP™In-House ASIC Design

3 chip series (NS01/NS02/NS03) across 6 generations. UMC foundry, 0.18μm CMOS. Billions of probe sensors per biochip. 100% proprietary silicon IP — zero external IP, zero royalties.

NovaLINK™Patented Surface Chemistry

Probes embedded directly within engineered chip surface coating. Dual function: specificity (probe binding) and antifouling (rejecting ~7,000 blood proteins). Core trade secret.

NovaBIO™Proprietary Bio-Probes

In-house microfluidics buffer system. ZNA probes for minimal electrical interference. VHH nanobodies (~15 kDa) and IgG mAbs (CHO-expressed). 10+ antibody families from animal to IHC validation.

NovaKIT™Analyzer & Cartridge

~200-component reader with in-house firmware, touch panel, barcode scanner, motion control. 300×200×250mm, 3–4 kg. Hospital compliance: patient ID, sample tracking, kit lot management.

NovaAI™Signal Intelligence

Proprietary signal-to-noise algorithms at femtogram sensitivity. Binding curve dynamics, systematic noise subtraction, chip-to-chip compensation. Smart manufacturing QC.

NovaCRO™Clinical Biobank & Lab

~100K bacterial isolates from CGMH (linked to clinical data). 394 species characterized. PET-validated AD samples. WGS library under construction. Certified contract lab.

Semiconductor DNA

First-in-class bio-fabless design house. Inspired by the fabless semiconductor paradigm, we develop and own 100% of our silicon IP.

Semiconductor IC Design Model Applied to IVD

As a direct customer of UMC, a leading semiconductor foundry in Taiwan, we maintain the flexibility to rapidly iterate chip designs while leveraging the cost advantages of mature-node manufacturing on 8-inch wafers. Our analogue ASIC is built on extended-gate FET (EG-FET) architecture and purpose-designed for ultra-sensitive biomarker detection.

100% Silicon IP Built from Ground Up

Different from many IC design houses that rely heavily on standard IP blocks and automated EDA tool flows, we have developed our own silicon IP. Our core sensing architecture, layout strategy, and signal chain design are proprietary. This allows us to preserve both performance differentiation and capture full economic value.

Billions of probe sensors per biochip

Unprecedented detection density: Approximately 2.4 billion probe sensor sites per biochip, 300M per sensing block (0.5 mm²), 4M per sensing unit (6 μm²). Manufactured at UMC on 0.18μm CMOS.

Chip Portfolio

Six successful chip generations. Each manufactured at UMC in production lots of 25 wafers (~50K chips).

NS01C

FET-Based Biosensing with Intrinsic Control

Field-effect transistor biosensing architecture for surface-charge detection of up to eight target molecules. 3×3 mm die, approximately 2.4 billion probe sensor sites. All current pipeline products built on NS01C.

NS02A

Array Sensor for High-Throughput

High-density array configuration for scalable multiplexing. Suited for pathogen panels and antimicrobial resistance (AMR) profiling across multiple genetic markers.

NS03A

Photoelectric Hybrid Detection

Complementary photoelectric sensing module for hybrid detection strategies. Enables optical-electronic integration for expanded assay flexibility.

Full-Stack Biochemistry

Programmable, scalable and vertically integrated biochemistry — built into silicon.

NovaBIO™ — Microfluidics & Buffer System

Our microfluidics-based, fast-tracked sample and buffer system streamlines sample preparation and stabilizes complex biological inputs. By optimizing fluid dynamics at the microscale, NovaBIO™ ensures controlled analyte transport, efficient reaction kinetics, and minimized sample loss. Critical for time-sensitive conditions such as sepsis.

NovaLINK™ — Patented Surface Chemistry

Our proprietary chemistry platform, where probes are embedded directly within the engineered surface coating of the NovaChip™. Unlike conventional assays that rely on secondary labeling or optical amplification, NovaLINK™ integrates specificity at the material level. Our chemistry is not added on — it is built within.

High-Purity Antibodies: Engineered for Precision

Off-the-shelf antibodies often lack the purity required for our ultra-sensitive biochips. We designed and manufactured our own proprietary antibodies as bioprobes — tailored for exceptional specificity and stability.

VHH Nanobodies (~15 kDa)
Single-domain antibody fragments from camelid IgG. Superior thermal stability, deeper epitope access, uniform surface orientation.
IgG Monoclonal Antibodies (mAbs)
CHO cell expression systems — gold standard for therapeutic-grade biologics. High yield, batch-to-batch consistency.
ZNA DNA Probes
Zip nucleic acid probes that minimize electrical background noise on the FET chip surface.

Nosocomial Pathogen Strain Bank & WGS Library

In collaboration with Chang Gung Memorial Hospital. 700+ bacterial isolates accumulated over nearly 30 years. 206 isolates ready for whole-genome sequencing (WGS); 494 prepared for DNA extraction.

The BioFET Advantage: From Probes to Processors

A simple and seamless diagnostic workflow engineered for simplicity. Each step — from semiconductor fabrication to real-time results — minimizes complexity while maximizing performance.

01
Bare Chip

Precision fabricated at UMC. Rigorous electrical testing.

02
Functional Biochip

Proprietary bioprobe design and surface coating.

03
Apply Sample

Any molecule carrying electric charges.

04
Bio-Sensing

FET detects charge redistribution at chip surface.

05
Signal Reading

Real-time digital readout, clinically native.

06
AI Analytics

AI-powered clinical decision support.

Complete sample-to-answer workflow: ~60 minutes for sepsis pathogen identification

Prototype Products

Ready for clinical validation and pilot manufacturing

Prototype products — NovaReader and cartridges
NS01 silicon die
NS01 BioChip Die

CMOS FET biosensor at UMC

Sample preparation
Sample Preparation

Microfluidics-based handling

Disposable cartridge
Disposable Cartridge

Single-use NovaCHIP™ cartridge

Portable reader
Portable Reader

Compact POC reader

NVDFlow™

Automated BioChip Platform System

A flexible, validated BioChip workflow ready for real-world clinical integration. Complete IVD instrument designed in-house with ~200 components including touch panel, barcode scanner, motion control, and custom sensor PCB supporting 1–8 chips per run.

Cross-Platform Verified
Benchmarked vs. Quanterix SIMOA
Sample-to-Answer
Same-day results
Compact Reader (3–4 kg)
300×200×250mm footprint
Operational Flexibility
Resource-efficient deployment
NVDFlow™ Platform

Intellectual Property

A walled garden built on intellectual property. From chip to chemistry: fully protected.

40+ Patents Filed Worldwide

IP spans chip architecture, sensing circuitry, surface chemistry, reagent systems, and integrated diagnostic platforms.

Patent Protection: Securing core inventions and platform-level claims
Trade Secrets: Protecting implementation details, process know-how, and optimization methods
Operational Safeguards: Controlled knowledge access and disciplined documentation management

End-to-End Ownership

We are building a vertically integrated BioIC ecosystem — from bioprobes, biochips, and test result readers to diagnostic devices. From chip architecture and surface chemistry to assay development, firmware, analytics, and clinical validation, every layer of the stack is designed to work seamlessly together.

Zero external silicon IP. Zero royalties. The cleanest IP table in the diagnostic semiconductor space.

FET-Based Biosensor Competitive Landscape

Competitor data compiled from publicly available sources, Q1 2026.

NanoDx

  • Founded: 2010 / US
  • Device: Silicon nanowire FET
  • Challenge: Sensor reproducibility
  • Production: In development
  • Cost/Test: Not yet available
  • Capital: $18M (Series C, 2020) / ~$34M total

Paragraf

  • Founded: 2015 / UK
  • Device: Monolayer graphene FET
  • Challenge: Scalability, graphene uniformity
  • Production: Pilot production
  • Cost/Test: $143
  • Capital: $55M (Series C, 2025) / ~$140M total

NOVASCOPE

  • Founded: 2022 / US & Taiwan
  • Device: Extended-gate FET (CMOS)
  • Advantage: Standard CMOS, scalable
  • Production: Pilot production (UMC)
  • Target COGS: ~$10/test
  • Capital: $22.5M (Series A+B)

Note: COGS ~$10/test is a projected target at production volume. Competitor data from publicly available sources.

Clinical Evidence

Clinically Demonstrated Performance

Validated through IRB-approved protocols at Chang Gung Memorial Hospital, one of Asia's largest medical centers.

Sepsis — Lead Indication

Direct-from-Whole-Blood Detection

88 clinical samples, single-center validation at CGMH. LOD of 10² cfu/mL from non-cultured whole blood — pathogen ID in under 60 minutes vs. 2–7 days for blood culture.

Overall Accuracy0%
Sensitivity0%
Specificity0%
n = 88 clinical samplesSingle-center, IRB-approved7 sepsis pathogens + AMR genes

Data on file. Clinical performance may vary in multi-center trials.

Neurodegeneration — Platform Validation

NfL Biomarker Detection

Neurofilament light chain (NfL) is a pan-neurodegeneration biomarker elevated in AD, MS, ALS, TBI, and Parkinson's disease.

R² = 0.97–0.99

Correlation vs. Quanterix SIMOA (gold standard, self-correlation: 0.98–0.99)

Matching the $300,000+ gold standard on a desktop platform at a fraction of the cost. pTau 217/231 assays in development for AD-specific diagnosis. In-house antibody production provides a sustainable competitive moat.

Validated under IRB-approved protocol at Chang Gung Memorial Hospital. Published: Ciou et al., Biosens Bioelectron 2023;228:115174 (PMID: 36933321)

Limit of Detection

LOD of 10² cfu/mL from non-cultured whole blood (n=88, CGMH). Orders of magnitude improvement over culture-dependent methods. 1,000× sensitivity advantage over BioFire FilmArray (5×10⁵ cfu/mL LOD). Data on file.

10²
cfu/mL from whole blood

Antibody Validation — Human Brain IHC

In-house antibodies validated with immunohistochemistry on human brain tissue from Alzheimer's disease patients. The ultimate specificity validation.

P-tau 217 IHC staining
pTau-217 IHCHuman brain, AD parietal section
NfL IHC staining
NfL IHCHuman brain, axonal cytoplasm
pTau 181 IHC staining
pTau-181 IHCHuman brain, AD section (2000×)
GFAP IHC staining
GFAP IHCHuman brain, astrocyte marker

Clinical Biobank Statistics

Real clinical specimens powering probe design and validation

~100K
Bacterial Isolates
(from CGMH)
394
Species
Characterized
10+
Antibody
Families
88
Clinical Samples
Validated (Sepsis)
PET
Validated AD
Patient Samples

Products referenced herein are for Research Use Only (RUO). Not for use in diagnostic procedures unless specified. Clinical data presented is from IRB-approved research protocols.

Pipeline

Multi-Disease Platform

A single semiconductor platform addressing multiple high-value clinical applications. The chip does not care what molecule it detects — any electrically charged molecule captured by a surface-bound probe generates a detectable signal.

Biomarker Portfolio Under Development

Infectious Disease Neurodegeneration Oncology Veterinary
Probe Type NA Ab & NA NA Ab & NA
Biomarker Probes E. faecium
A. baumannii
K. pneumoniae
E. coli
E. faecalis
P. aeruginosa
S. aureus
+ AMR resistance genes
pTau 181/217/231
NfL
GFAP
S100B
TDP-43
α-synuclein
Amyloid β-42/40
APOE4 (NA)
EGFR
ALK
ROS1
BRAF
NTRK
RET
K-RAS
METex14
PRRSV
PEDV
PCV1/2/3/4
CSFV
PRV
SB

NA = Nucleic Acid; Ab = Antibody. Biomarkers listed are under development or in validation. Not FDA-cleared products.

Rapid Sepsis Pathogen Detection & AMR Profiling

Sepsis costs $24B annually in US hospitals. Each hour of delayed treatment increases mortality by 7.6% (Kumar et al., Crit Care Med 2006). Our platform delivers results from uncultured whole blood in under one hour.

Pathogens: E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, S. aureus, E. faecalis, E. faecium
AMR Panel: CTX-M, IMP, KPC, mcr-1a, mecA/C, MREJ, NDM, OXA-48-like, vanA/B, VIM
Stage: Product prototype → Clinical trials (2026) → Regulatory submission → Commercial launch
Sepsis clinical validation data
PlatformSpecimenTimeSensitivityPrice/Test
NOVASCOPEWhole blood<1 hr97% (n=88)*<$100 (target)
BioFire BCID2Cultured>1 day>90%$150–180
T2 BacteriaWhole blood<5 hrs91–96%$300–450
Roche EplexCultured<15 hrs>90%$180–220

*Single-center, n=88. Competitor data from publicly available sources. Novascope pricing is a projected target.

Neurodegeneration Biomarker Panel

With FDA approval of lecanemab (Leqembi) and donanemab (Kisunla), blood-based biomarker testing has become essential for patient screening. Current tests require $200K+ instruments and are confined to reference laboratories.

Biomarkers: pTau 181/217/231, NfL, GFAP, Aβ-42/40, α-synuclein, S100B, TDP-43, UCH-L1, APOE4
Validated: NfL (R² = 0.97–0.99 vs. Quanterix SIMOA)
In Development: pTau 217/231 — the competitive differentiator for AD-specific diagnosis
AD biomarker correlation data
PlatformStageTurnaroundMachine CostPrice/Test
NOVASCOPEUnder dev.Minutes<$50K (target)~$200 (target)
Fujirebio LumipulseFDA clearedHours–days~$200K~$600
Roche ElecsysFDA clearedHours–days~$200K~$600
Quanterix SIMOALDT serviceDays/batch$300–400K~$500

Novascope pricing and machine cost are projected targets. Competitor data from publicly available sources.

Liquid Biopsy / Oncology

Nucleic acid-based detection of actionable mutations: EGFR, ALK, ROS1, BRAF, NTRK, RET, K-RAS, METex14. ctDNA detection via FET platform. 168 EGFR actionable mutations targeted.

Early discovery stage

Animal Health & Veterinary

POC diagnostics for livestock health monitoring. Probes for PRRSV, PEDV, PCV1-4, CSFV, PRV, and SB. Addressing the veterinary diagnostics market.

Probe development stage

Extended Sepsis Panel

Expansion to 60+ bacterial species with comprehensive resistance gene profiling. Targeting the $25B+ blood culture market.

Pipeline planning

Respiratory & Other

Respiratory pathogen panel, HCV genotyping, food safety testing. Each new application requires only new probes and assay protocol — chip, reader, and software are reusable.

Pipeline planning
Solutions

Clinical & Care Settings

From reference laboratories to point-of-care clinics — a single platform, multiple deployment configurations.

Manual POC Reader

Single-test portable reader for point-of-care clinics. Compact, battery-capable, touchscreen interface. Ideal for emergency departments, rural clinics, and bedside testing.

Protein Automation (NVDFlow™)

Bench-top automated platform for neurodegeneration biomarkers. 1–8 chips per run. Sample-to-answer workflow. Cross-platform verified against Quanterix SIMOA.

Bacteria Automation

High-throughput instrument for sepsis pathogen detection and AMR profiling. 64-test capacity. Designed for hospital clinical microbiology laboratories.

Revenue Architecture

Multiple revenue streams from a single semiconductor platform

IVD Diagnostics (Primary)

Razor/blade model — instrument placement + recurring cartridge sales. Target: instrument <$50K, test ~$100–200.

NovaBIO™ Reagent Products

Antibody and ELISA kit sales. Near-term revenue from proprietary antibodies. 77 clones developed, 6 commercially available.

Platform Licensing & OEM

White-label biochip platform for strategic partners. Active discussions with industry players for co-development.

CRO & Biobank Services

Contract lab services leveraging ~100K clinical isolate biobank. Revenue from validation testing and regulatory studies.

End-to-End Value Chain

DESIGN
IC Design & Tape-out
In-house
FOUNDRY
UMC Fabrication
0.18μm CMOS
CHEMISTRY
Surface & Bio-Probes
In-house
HARDWARE
Reader & Cartridge
In-house
SOFTWARE
AI & Analytics
In-house
CLINICAL
CRO & Regulatory
In-house
Market Context

Why Now

Three converging forces create an unprecedented window for semiconductor-powered diagnostics.

The AMR Crisis

1.27M
Deaths per year

1.27M deaths annually from antimicrobial resistance (WHO/Lancet 2019). Sepsis costs $24B in US hospitals. Every 60 minutes of delay increases mortality 7.6% (Kumar et al., 2006; PMID 16625125). Blood culture is fundamentally too slow.

The AD Drug Revolution

6M+
Americans with AD

FDA approval of lecanemab ($26,500/year) and donanemab creates mandatory screening demand. Current testing costs $500–$1,250 per test at reference labs. 6+ million Americans with AD need affordable, decentralized biomarker testing.

Semiconductor Advantage

~$10
Target COGS vs $143+

Taiwan's semiconductor ecosystem provides unmatched precision and cost. As the first bio-fabless company at UMC, target COGS of ~$10/test vs. $143+ for competitors. The same cost curve that transformed computing, communications, and mobile.

Investors

The Investment Opportunity

Novascope sits at the intersection of semiconductors and diagnostics — with a defensible platform, clean IP, and clear path to commercialization.

De-Risked

Technology validated: 3 chip series, 6 generations wafer-out at UMC in production lots
Manufacturing: Direct UMC customer. ISO 13485 certified. QMS under way
IP fortress: 40+ patents worldwide. Zero external silicon IP — no royalties
Team: 50+ employees, Stanford Top 2% scientists, former FDA Division Director
Clinical biobank: ~100K bacterial isolates from CGMH. PET-validated AD samples
Global: Taiwan HQ + San Diego lab. US advisory board (UCSD, Harvard, U Maryland)

Key Risks & Mitigants

Regulatory timeline

TFDA-first strategy accelerates FDA/CE pathway. Keith Chan (former FDA Division Director) leads regulatory.

Clinical adoption

Partnerships with CGMH, NTUH, VGH. US advisory board from top medical centers.

Competition

Only standard CMOS FET platform in the space. Complete E2E ownership eliminates royalty exposure.

Scale-up

UMC foundry ensures semiconductor-grade manufacturing repeatability at volume.

Funding & Milestone Timeline

Pre-Seed 2022 Seed 2023 Series A $13.5M | 2024 Series B $8.9M | 2025 Total: $22.5M Series B+ $10–15M target

Unit Economics: The Semiconductor Cost Curve

$35 $25 $20 $15 $10 COGS / Unit $31 2,000 units/mo $26 5,000 units/mo $21 10,000 units/mo ~$10 50,000 target 56% margin 63% margin 70% margin 86% margin COGS at Scale (ASP: $70)

Projected COGS at various production volumes. Margins calculated at $70 average selling price. Data on file.

Series B — Use of Funds

Raised: $8.9M (2025) | Total capital raised to date: $22.5M

Clinical Trials

Multi-site validation, regulatory submissions

Manufacturing

Pilot-to-production scale-up

US Operations

San Diego lab, FDA filings

Commercial Prep

Distribution partnerships, market access

Newsroom

News & Events

DEC 2025

Healthcare+ Expo Taiwan 2025

Novascope showcased the NVDFlow™ automated BioChip platform and sepsis detection capabilities at Asia's largest healthcare trade event in Taipei.

NOV 2025

Medica 2025 — Düsseldorf, Germany

Presentation of our BioFET-based clinical diagnostics platform at the world's largest medical trade fair, engaging with European distribution and partnership prospects.

2023

Publication: pTau-217 SGFET Biosensor

Ciou et al., "Solution-gated FET biosensor for pTau-217 detection." Biosensors and Bioelectronics 2023;228:115174. PubMed (PMID: 36933321)

2024

Sepsis Pathogen Detection — Clinical Validation Results

Third-party clinical validation at Chang Gung Memorial Hospital. Direct-from-whole-blood detection achieving 98% accuracy across 88 clinical samples. Manuscript in preparation.

2024

NfL Head-to-Head vs. Quanterix SIMOA

Platform validation demonstrating R²=0.97–0.99 correlation for neurofilament light chain against the gold standard SIMOA platform. Data on file.

Partners

Strategic Partnerships

Building a global ecosystem across semiconductor manufacturing, clinical validation, and academic research.

Semiconductor Manufacturing

UMC (United Microelectronics Corp.)

World's 3rd largest dedicated semiconductor foundry. Novascope is a direct customer ordering production lots of 25 eight-inch wafers (~50K chips per lot). 0.18μm CMOS process — the mature, high-yield node ideal for analog biosensor ICs.

Clinical Validation

Chang Gung Memorial Hospital

Asia's largest private medical system with 10,000+ beds across 7 hospitals. IRB-approved clinical validation protocols. Source of ~100K clinical isolates spanning nearly 30 years. 394 bacterial species characterized. Multi-decade collaboration in clinical microbiology.

US Advisory & Research

UC San Diego / Harvard / U Maryland

US advisory board members from leading medical centers provide clinical expertise in sepsis, emergency medicine, and critical care. San Diego validation laboratory for US studies.

Leadership

Team

Deep expertise spanning IC design, clinical medicine, regulatory affairs, and capital markets.

Dorothy Chiu, MS

Dorothy Chiu, MS

Chairperson & CEO

20+ years IC & biotech. Former VP, Richtek Technology (MediaTek).

Led IC product lines at Richtek (acquired by MediaTek). Deep expertise in semiconductor product management, manufacturing operations, and scaling startups to production. Transitioned from IC industry to biotech to build the first bio-fabless diagnostics company.
+ More
Chang-Fu Kuo, MD, PhD

Chang-Fu Kuo, MD, PhD

Co-Founder & CSO

Stanford Top 2% scientist. AI & clinical research at Chang Gung. Board Director.

Professor of Rheumatology, Chang Gung University. Former R&D Director, AI Medical Center at CGMH. Extensive publications in clinical AI, biomarker discovery, and translational medicine. Key architect of Novascope's clinical validation strategy and CGMH partnership.
+ More
Keith Chan, PhD

Keith Chan, PhD

VP, US Regulatory & IP

Former FDA Division Director, Office of Generic Drugs. UCSD Bioengineering. 20+ years regulatory. Board Director.

Former Division Director at FDA Office of Generic Drugs. Co-founder of GloboMax (acquired). UCSD Bioengineering faculty. 20+ years navigating FDA regulatory pathways for medical devices and diagnostics. Leads Novascope's US regulatory strategy and IP portfolio management.
+ More
James Wu, PhD

James Wu, PhD

VP, IC Design

Former Deputy Director General, ERSO/ITRI. Microelectronics, MEMS, and medical devices.

Joyce Chen

Joyce Chen

VP, Biochemistry

Surface chemistry & antibody engineering. Leads NovaBIO™ & NovaLINK™ platforms.

Emily Liu, CFA, CAIA

Emily Liu, CFA, CAIA

Finance & IR Director

25 years deep-tech equity research. Taipei & London markets.

US Scientific Advisory Board (Sepsis KOLs)

Gabriel Wardi, MD — UC San Diego. AI-driven sepsis prediction and emergency medicine.
Nathan Shapiro, MD, MPH — Harvard / Beth Israel Deaconess. NEJM & JAMA published. Sepsis biomarkers.
Michael McCurdy, MD — University of Maryland. Sepsis resuscitation and critical care specialist.

Join Us

We're building the future of diagnostics at the intersection of semiconductors and biology. 50+ team members across Taiwan and the US, and growing. Contact us at bd@novascopedx.com to explore opportunities.

Contact

Get in Touch

Emily Liu, CFA, CAIA

Emily Liu, CFA, CAIA

Finance & IR Director
25 years of deep-tech equity research experience
Investor Relations
emily.liu@novascopedx.com
Business Development
bd@novascopedx.com
General Inquiry
bd@novascopedx.com
Taiwan HQ
Zhubei, Hsinchu, Taiwan
US Operations
San Diego, CA, USA